Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and PK of BIIB061 in Healthy Volunteers
NCT02071121Phase 1Completed
- Sponsor
- Biogen
- Start
- Dec 2013
- Primary completion
- Sep 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of BIIB061 in multiple sclerosis (MS) (6 arms), sponsored by Biogen. Primary endpoint: Number of participants that experience adverse events (AEs) and Serious Adverse Events (SAEs) at 28 days. Started Dec 2013; status: completed.
02
Drugs
BIIB061
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT02071121.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02071121.